Skip to content
The FORTIFIEDx project has received funding from the Horizon Europe programme under grant agreement Nº 101092049

Discover FORTIFIEDx

Multifunctional microfluidic patch
for infectious diseases diagnosis

The FORTIFIEDx project aims to revolutionize the point-of-care in vitro diagnostic (POC IVD) field by making use of novel multifunctional biocompatible polymers and their (micro)structuring with mass fabrication technology to develop for the first time a true sample-to-result POC test.

In vitro diagnostic (IVD) technologies have revolutionized healthcare, yet remain confined to the laboratories. As witnessed during the COVID-19 pandemic, this traditional centralized approach was not sufficient to prevent and manage viral outbreak because it massively failed to deliver quick and cost-effective diagnosis. The pandemic further emphasized the growing need to urgently bring lab-quality diagnosis to the hands of end users (i.e. point-of-care, POC).

The FORTIFIEDx consortium will develop a FORTIFIEDx microfluidic-based patch capable of both biofluids (self-)sampling via hollow microneedles (HMN) and immediate analysis of this sample on the very same patch in a completely self-powered manner. Two unmet clinical needs, posing epidemic/pandemic threats to both the developed and developing world, are selected:

Sexually Transmitted Diseases (STD)

Simultaneous diagnosis of HIV and Syphilis will enable timely diagnosis of patients not able to reach centralized settings due to stigma or financial difficulties.

Viral Haemorrhagic Fevers (VHF)

Detection of Ebola and Lassa viruses will enable battling their highly contagious and deadly outbreaks.

FORTIFIEDx value chain

FORTIFIEDx value chain covers the aspects from investigation of multifunctional materials to their exploitation for unmet clinical needs with the aim to deliver a disposable and self-powered microfluidic-based IVD POC test.
Fortified Value
To tackle this challenging aim, the interdisciplinary and experienced FORTIFIEDx consortium (2 universities, 5 research institutes and 2 SMEs from 6 countries) will combine insights from material science, engineering and microfabrication, microfluidic technology development, bioassay development, clinical validation and life cycle assessment.
×ATENCIÓ: Cookies no configurades en l'idioma actual. Revisa la teva configuració al plugin, gràcies!